Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Sibongile Walaza Clear advanced filters

  • Introduction of pneumococcal conjugate vaccines in South Africa has led to reductions in vaccine serotype-related invasive disease. Here, the authors perform a genomic surveillance study to evaluate the impact of vaccines on the population structure of S. pneumoniae.

    • Cebile Lekhuleni
    • Kedibone Ndlangisa
    • Mignon du Plessis
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-12

  • South Africa experienced a resurgence in COVID-19 in 2022 driven by Omicron subvariants BA.4 and BA.5. Here, the authors investigate the severity of infections caused by these subvariants, and find no difference in the risk of severe outcomes when compared to Omicron BA.1, whilst all Omicron subvariants were less severe than Delta.

    • Nicole Wolter
    • Waasila Jassat
    • Cheryl Cohen
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-8

  • Passive immunisation for respiratory syncytial virus for infants is recommended by the World Health Organization but products currently available have limited duration of protection. Here, the authors investigate the age distribution of infant hospitalisation for respiratory syncytial virus to inform optimal timing of immunisation.

    • Ling Guo
    • Sebastien Kenmoe
    • Eva Molero
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-13

  • Vaccination against invasive pneumococcal disease is recommended for older adults but the optimal age group to target has not been determined and may vary by epidemiological setting. Here, the authors use statistical modelling to estimate the optimal ages for vaccination in Brazil, England, Malawi, and South Africa.

    • Deus Thindwa
    • Samuel Clifford
    • Stefan Flasche
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-8

  • The 501Y.V2 variant of SARS-CoV-2 in South Africa became dominant over other variants within weeks of its emergence, suggesting that this variant is linked to increased transmissibility or immune escape.

    • Houriiyah Tegally
    • Eduan Wilkinson
    • Tulio de Oliveira
    Research
    Nature
    Volume: 592, P: 438-443

  • Interrogation of 1,365 near whole-genome sequences of SARS-CoV-2 variants isolated in South Africa during the first 6 months of the global pandemic reveals three major monophyletic lineages responsible for more than half of the infections in the country and underscores the value of integrating genomic surveillance methods to inform the national pandemic response.

    • Houriiyah Tegally
    • Eduan Wilkinson
    • Tulio de Oliveira
    Research
    Nature Medicine
    Volume: 27, P: 440-446

  • In this study, the authors provide a global overview of SARS-CoV-2 genome sequencing, and estimate the proportion of cases sequenced and time to genome upload. They identify disparities and highlight the need to strengthen surveillance in lower and middle income countries.

    • Anderson F. Brito
    • Elizaveta Semenova
    • Nuno R. Faria
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-13

  • Cross-neutralization assays of early variants and the 501Y.V2 variant of SARS-CoV-2 show that plasma from individuals infected with 501Y.V2 effectively neutralizes all variants, indicating that a vaccine that targets 501Y.V2 may also be effective against other SARS-CoV-2 variants.

    • Sandile Cele
    • Inbal Gazy
    • Alex Sigal
    Research
    Nature
    Volume: 593, P: 142-146